{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Covid",
      "Genetic diversity",
      "SARS CoV 2",
      "Vaccine efficacy",
      "Variants"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36108974",
  "DateCompleted": {
    "Year": "2022",
    "Month": "11",
    "Day": "24"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "22"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "09",
        "Day": "13"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.idnow.2022.09.008",
      "S2666-9919(22)00190-7"
    ],
    "Journal": {
      "ISSN": "2666-9919",
      "JournalIssue": {
        "Volume": "52",
        "Issue": "8S",
        "PubDate": {
          "Year": "2022",
          "Month": "Nov"
        }
      },
      "Title": "Infectious diseases now",
      "ISOAbbreviation": "Infect Dis Now"
    },
    "ArticleTitle": "SARS-CoV-2 genetic diversity: Its impact on vaccine efficacy.",
    "Pagination": {
      "StartPage": "S2",
      "EndPage": "S3",
      "MedlinePgn": "S2-S3"
    },
    "Abstract": {
      "AbstractText": [
        "SARS CoV 2 S-glycoproteins play a crucial role in the entry steps of viral particles. Due to their surface location, they are the main target for host immune responses and the focus of most vaccine strategies. The D614G mutation identified in late January became dominant during March 2020, rendering SARS-CoV-2 more infectious. In April 2020, the Alpha, Beta and Gamma variants emerged simultaneously in Asia, South Africa, and South America, respectively. They were 1.6 to 2 times more transmissible than the ancestral strain. The currently dominant Omicron variant (BA.2) is not a direct descendant from the D614G lineage, but rather emerged from the BA.1 variant (as did BA.4 and BA.5). It is substantially different from all the other variants. It presents significantly reduced susceptibility to antibody neutralization: after 2 doses of mRNA-vaccine, neutralizing titers to Omicron are 41 to 84 times lower than neutralization titers to D614G. That said, a booster dose of mRNA-vaccine increases Omicron neutralization titers and reduces the risk of severe infection."
      ],
      "CopyrightInformation": "Copyright \u00a9 2022. Published by Elsevier Masson SAS."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Laboratoire de virologie, Institut des Agents Infectieux, CHU Lyon, Lyon, France."
          }
        ],
        "LastName": "Lina",
        "ForeName": "B",
        "Initials": "B"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service Universitaire des Maladies Infectieuses et du Voyageurs, CH Dron, 59200 Tourcoing, France. Electronic address: bauerjules@gmail.com."
          }
        ],
        "LastName": "Bauer",
        "ForeName": "J",
        "Initials": "J"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "France",
    "MedlineTA": "Infect Dis Now",
    "NlmUniqueID": "101775152",
    "ISSNLinking": "2666-9919"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Viral"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "RNA, Viral"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "RNA, Messenger"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Neutralization Tests"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Antibodies, Viral"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vaccine Efficacy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "RNA, Viral"
    },
    {
      "QualifierName": [
        "epidemiology",
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Genetic Variation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "RNA, Messenger"
    }
  ],
  "CoiStatement": "Declaration of interest The authors declare no conflict of interest"
}